×
Request Free Sample ×
Ticagrelor Market Research Report - Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Ticagrelor Market

ID: MRFR/Pharma/0324-CR
101 Pages
Kinjoll Dey
July 2019

Ticagrelor Market Market Research Report: Size, Share, Trend Analysis by Dosage (Mg) (90 MG and 60 MG), Route of Administration (Oral and Nasogastric Tube), Application (Acute Coronary Syndrome and Heart Surgeries (Angioplasty, Stent Placement and Coronary Artery Bypass Graft)) End User (Hospitals and Clinics and Ambulatory Centers) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Ticagrelor Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Ticagrelor Market Summary

As per MRFR analysis, the Ticagrelor Market Size was estimated at 2024.94 USD Million in 2024. The Ticagrelor industry is projected to grow from 2172.45 in 2025 to 3916.71 by 2035, exhibiting a compound annual growth rate (CAGR) of 6.14 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Ticagrelor market is poised for growth driven by increasing demand for antiplatelet therapies and innovations in drug formulation.

  • The demand for antiplatelet therapies continues to rise, particularly in North America, which remains the largest market for Ticagrelor.
  • Innovations in drug formulation are enhancing the efficacy and safety profiles of Ticagrelor, appealing to healthcare providers and patients alike.
  • Collaborative efforts in research are fostering advancements in treatment protocols, especially in the Acute Coronary Syndrome segment, which is the largest market segment.
  • The increasing incidence of cardiovascular diseases and the growing geriatric population are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 2024.94 (USD Million)
2035 Market Size 3916.71 (USD Million)
CAGR (2025 - 2035) 6.14%

Major Players

AstraZeneca (GB), Boehringer Ingelheim (DE), Sanofi (FR), Bristol-Myers Squibb (US), Pfizer (US), Novartis (CH), Mylan (US), Teva Pharmaceutical Industries (IL)

Ticagrelor Market Trends

The Ticagrelor Market is currently experiencing notable developments, driven by an increasing prevalence of cardiovascular diseases and a growing awareness of the importance of antiplatelet therapies. This medication, primarily utilized for the prevention of thrombotic events in patients with acute coronary syndrome, has gained traction due to its efficacy and safety profile. The market landscape appears to be evolving, with pharmaceutical companies investing in research and development to enhance formulations and delivery methods. Furthermore, the rising geriatric population, which is more susceptible to heart-related ailments, is likely to contribute to the sustained demand for Ticagrelor. In addition, the competitive environment within the Ticagrelor Market is intensifying, as various players strive to capture market share through innovative strategies. Collaborations and partnerships among key stakeholders, including healthcare providers and research institutions, seem to be on the rise, potentially leading to improved patient outcomes. Regulatory bodies are also playing a crucial role in shaping the market dynamics by ensuring that new entrants meet safety and efficacy standards. Overall, the Ticagrelor Market appears poised for growth, driven by advancements in medical science and an increasing focus on preventive healthcare.

Rising Demand for Antiplatelet Therapies

The demand for antiplatelet therapies, particularly Ticagrelor, is on the rise due to an increasing incidence of cardiovascular diseases. As healthcare providers emphasize the importance of preventing thrombotic events, more patients are being prescribed this medication, leading to a broader market reach.

Innovations in Drug Formulation

Pharmaceutical companies are focusing on innovations in drug formulation and delivery methods for Ticagrelor. These advancements aim to enhance patient compliance and improve therapeutic outcomes, thereby potentially expanding the market's appeal to a wider audience.

Collaborative Efforts in Research

There is a noticeable trend towards collaborative efforts among pharmaceutical companies, healthcare providers, and research institutions. These partnerships are likely to foster the development of new treatment protocols and improve the overall efficacy of Ticagrelor, thereby influencing market dynamics.

Ticagrelor Market Drivers

Market Growth Projections

The Global Ticagrelor Market Industry is projected to experience robust growth over the coming years. With an estimated market value of 0.97 USD Billion in 2024, the industry is on a trajectory to reach 4.0 USD Billion by 2035. This growth is underpinned by a compound annual growth rate of 13.73% from 2025 to 2035. Such projections indicate a strong demand for Ticagrelor Market, driven by factors such as increasing cardiovascular disease prevalence, advancements in drug formulations, and enhanced healthcare access in emerging markets. These metrics highlight the potential for sustained growth in the Global Ticagrelor Market Industry.

Growing Awareness and Education

The increasing awareness and education regarding the importance of antiplatelet therapy contribute significantly to the Global Ticagrelor Market Industry. Healthcare providers are actively promoting the benefits of Ticagrelor Market in preventing cardiovascular events, leading to higher prescription rates. Initiatives by organizations such as the American Heart Association emphasize the need for effective treatment options, thereby influencing patient choices. This heightened awareness is likely to drive market growth, as more patients seek out Ticagrelor Market as a viable treatment option. The anticipated compound annual growth rate of 13.73% from 2025 to 2035 further illustrates this trend.

Advancements in Drug Formulations

Innovations in drug formulations and delivery mechanisms are propelling the Global Ticagrelor Market Industry forward. Recent advancements have enhanced the efficacy and safety profiles of Ticagrelor Market, making it a preferred choice among healthcare professionals. For example, the development of fixed-dose combinations with other antiplatelet agents has shown promising results in clinical trials. These innovations not only improve patient adherence but also expand the therapeutic applications of Ticagrelor Market. As a result, the market is anticipated to experience substantial growth, potentially reaching 4.0 USD Billion by 2035, driven by these advancements.

Emerging Markets and Accessibility

The expansion of healthcare infrastructure in emerging markets is a crucial driver for the Global Ticagrelor Market Industry. As countries invest in improving healthcare access, the availability of Ticagrelor Market is likely to increase, reaching a broader patient population. For example, nations in Asia and Africa are witnessing significant improvements in healthcare delivery systems, which facilitate the distribution of essential medications. This trend is expected to contribute to the overall market growth, as more patients gain access to effective antiplatelet therapies. The Global Ticagrelor Market Industry is poised to benefit from these developments, enhancing its reach and impact.

Increasing Cardiovascular Diseases

The rising prevalence of cardiovascular diseases globally is a primary driver for the Global Ticagrelor Market Industry. As heart-related ailments continue to escalate, the demand for effective antiplatelet therapies like Ticagrelor Market is expected to grow. For instance, the World Health Organization indicates that cardiovascular diseases account for approximately 32% of all global deaths. This alarming statistic underscores the urgent need for effective treatment options. Consequently, the Global Ticagrelor Market Industry is projected to reach 0.97 USD Billion in 2024, reflecting a significant response to this health crisis.

Regulatory Approvals and Guidelines

The role of regulatory approvals and clinical guidelines cannot be understated in the Global Ticagrelor Market Industry. Regulatory bodies are increasingly recognizing the efficacy of Ticagrelor Market, leading to expedited approvals for new indications. For instance, recent updates in clinical guidelines recommend Ticagrelor Market as a first-line treatment for certain patient populations. Such endorsements not only enhance the drug's credibility but also encourage healthcare providers to prescribe it more frequently. This regulatory support is expected to bolster market growth, as the industry adapts to evolving clinical practices and guidelines.

Market Segment Insights

By Application: Acute Coronary Syndrome (Largest) vs. Stroke Prevention (Fastest-Growing)

In the Ticagrelor market, the application segment demonstrates diverse distribution across various categories. The Acute Coronary Syndrome application holds the largest market share, reflecting its critical role in managing patients at risk of heart attacks. Other applications such as Myocardial Infarction and Peripheral Artery Disease show significant presence, but they lag behind the dominating Acute Coronary Syndrome segment. Stroke Prevention, while smaller, is progressively gaining traction, driven by increasing awareness about stroke risk factors and preventive measures.

Myocardial Infarction (Dominant) vs. Peripheral Artery Disease (Emerging)

Myocardial Infarction represents a dominant application in the Ticagrelor market, primarily due to its high prevalence and the acute need for effective treatment options. It caters to a vast patient population in urgent healthcare settings, solidifying its market position. Conversely, Peripheral Artery Disease is emerging as a key player, propelled by changing demographics and rising incidences associated with lifestyle diseases. Its growth is fueled by innovations in treatment modalities and heightened awareness, encouraging healthcare professionals to adopt Ticagrelor in managing this condition. The divergence in their market roles reveals a landscape where traditional applications remain influential while newer segments gain momentum.

By Route of Administration: Oral (Largest) vs. Intravenous (Fastest-Growing)

In the Ticagrelor Market, the Route of Administration segment is prominently dominated by Oral administration, which significantly contributes to the overall uptake of the drug. This method holds the majority market share due to its convenience and patient compliance, as many patients prefer an oral route over others. Conversely, Intravenous administration, though smaller in share, is witnessing an upward trend, especially in emergency and acute care settings, driven by the immediate onset of action it offers. The growth of the Intravenous segment is propelled by its increasing application in critical care, where rapid therapeutic effects are essential. Additionally, advancements in delivery technologies and rising prevalence of conditions requiring immediate antiplatelet therapy are further fostering demand. As healthcare providers increasingly recognize the value of quick intervention, this segment is expected to continue expanding at a faster pace than its oral counterpart.

Oral (Dominant) vs. Intravenous (Emerging)

The Oral route is the dominant method of administration in the Ticagrelor Market, appreciated for its simplicity and ease of use, especially in outpatient settings. Patients show a preference for oral formulations due to their non-invasive nature, which also supports better adherence to treatment plans. On the other hand, the Intravenous route is emerging as a critical alternative, primarily used in hospital environments where rapid action is necessary. This method is particularly advantageous in acute situations, allowing healthcare professionals to administer the drug quickly and monitor patient responses more effectively. While currently representing a smaller share of the market, the intravenous segment is gaining traction among clinicians, driven by the growing emphasis on immediate care and advancements in infusion technology.

By Patient Demographics: Adult Patients (Largest) vs. Geriatric Patients (Fastest-Growing)

In the Ticagrelor market, patient demographics play a crucial role in shaping treatment strategies. Adult patients currently represent the largest segment, encompassing a diverse age range and a wide variety of cardiovascular issues. This group’s substantial size is attributed to the higher prevalence of heart diseases among adults, resulting in a sustained demand for efficient antiplatelet therapies like Ticagrelor. Conversely, geriatric patients are emerging as a fast-growing demographic, influenced by the increasing life expectancy and the rising incidence of cardiovascular conditions in older adults.

Adult Patients: Dominant vs. Geriatric Patients: Emerging

Adult patients dominate the Ticagrelor market due to their significant health needs driven by lifestyle-related cardiovascular issues. This segment benefits from established treatment guidelines and a robust patient network, facilitating broader accessibility to Ticagrelor. On the other hand, geriatric patients represent the emerging segment with unique treatment considerations, including polypharmacy and altered pharmacokinetics. As healthcare systems adapt to cater to the aging population, special attention is directed towards optimizing Ticagrelor use among older adults. This has prompted research into tailored dosing strategies, emphasizing geriatric patients' needs while balancing efficacy and safety.

By Therapeutic Area: Cardiology (Largest) vs. Neurology (Fastest-Growing)

In the Ticagrelor market, the therapeutic area of cardiology holds the largest market share among the available segments, driven by the high prevalence of cardiovascular diseases globally. The focus on innovative treatments and an increase in patient management strategies concerning heart-related ailments are factors that enhance the market's stability within this segment. Neurology, while currently smaller in market share compared to cardiology, is witnessing rapid growth, primarily due to rising awareness of neurological disorders and advancements in treatment options such as Ticagrelor for secondary prevention in stroke patients.

Cardiology (Dominant) vs. Neurology (Emerging)

Cardiology represents the dominant segment in the Ticagrelor market, characterized by a robust demand for anticoagulants and antiplatelet therapies aimed at reducing cardiac events. Clinicians and healthcare providers prioritize this area due to its significant impact on patient health outcomes. In contrast, neurology is emerging as a significant area of interest, with increasing research focusing on its applications in preventing recurrent strokes. This segment is gaining traction as healthcare systems recognize the importance of addressing neurovascular issues that complement existing cardiac therapies. Together, these segments highlight a dual approach in treating patients with cardiovascular and neurological comorbidities.

By Formulation Type: Tablet (Largest) vs. Injection (Fastest-Growing)

In the Ticagrelor Market, the formulation type segment consists of Tablets and Injections, with Tablets holding the larger portion of the market share. This preference for Tablets can be attributed to their ease of use, established efficacy, and acceptance among patients and healthcare providers. On the other hand, Injections represent a smaller segment but are gaining traction due to specific patient demographics that require rapid onset of action and controlled delivery, which are typically facilitated through injectable formulations.

Formulation Type: Tablet (Dominant) vs. Injection (Emerging)

Tablets are currently the dominant formulation type in the Ticagrelor Market, largely due to their convenience and patient compliance, allowing for easy administration and dosage adherence. They cater to a broad patient base, ensuring that control of platelets is managed effectively in chronic conditions. Conversely, Injections are emerging as a vital option, particularly in acute care settings, where rapid therapeutic response is critical. The trend toward injectable alternatives is driven by advancements in formulation technology and the growing confidence of healthcare professionals in their administration. Coupled with the push for novel therapies, the Injection segment is positioned to capture a more significant market share as clinical practices evolve.

Get more detailed insights about Ticagrelor Market
Request Free Sample

Regional Insights

North America : Market Leader in Ticagrelor

North America continues to lead the Ticagrelor market, holding a significant share of 1012.47 million in 2024. The growth is driven by increasing cardiovascular diseases, rising awareness about antiplatelet therapies, and favorable reimbursement policies. Regulatory support from agencies like the FDA has also catalyzed market expansion, ensuring that innovative treatments are accessible to patients. The competitive landscape is robust, with key players such as AstraZeneca, Bristol-Myers Squibb, and Pfizer dominating the market. The U.S. is the primary contributor, supported by advanced healthcare infrastructure and high healthcare expenditure. The presence of established pharmaceutical companies fosters innovation and competition, further solidifying North America's position in The Ticagrelor.

Europe : Emerging Market Dynamics

Europe's Ticagrelor market is projected to reach 800.0 million by 2025, driven by increasing incidences of cardiovascular diseases and a growing aging population. Regulatory frameworks across EU countries are becoming more favorable, promoting the adoption of innovative therapies. The European Medicines Agency (EMA) has been instrumental in expediting the approval processes for new treatments, enhancing market accessibility. Leading countries in this region include Germany, France, and the UK, where healthcare systems are increasingly prioritizing cardiovascular health. Major players like Sanofi and Boehringer Ingelheim are actively investing in research and development to enhance their product offerings. The competitive landscape is characterized by strategic partnerships and collaborations aimed at improving patient outcomes and expanding market reach.

Asia-Pacific : Emerging Powerhouse in Healthcare

The Asia-Pacific region is witnessing a burgeoning Ticagrelor market, projected to reach 150.0 million by 2025. This growth is fueled by rising healthcare expenditures, increasing awareness of cardiovascular diseases, and improving healthcare infrastructure. Regulatory bodies in countries like Japan and Australia are enhancing their frameworks to facilitate quicker access to essential medications, thereby driving market demand. Key players in this region include Novartis and Teva Pharmaceutical Industries, which are focusing on expanding their presence through strategic collaborations and local partnerships. Countries like China and India are emerging as significant markets due to their large populations and increasing prevalence of heart-related ailments. The competitive landscape is evolving, with a focus on affordability and accessibility of Ticagrelor treatments.

Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually developing its Ticagrelor market, with a size of 62.47 million projected for 2025. The growth is primarily driven by increasing healthcare investments and a rising burden of cardiovascular diseases. Governments are beginning to recognize the importance of cardiovascular health, leading to improved healthcare policies and funding for essential medications. Countries like South Africa and the UAE are at the forefront of this market, with increasing healthcare access and awareness. Key players such as Mylan are exploring opportunities to penetrate this market, focusing on affordability and local partnerships. The competitive landscape is still developing, but there is significant potential for growth as healthcare systems evolve and expand their capabilities.

Ticagrelor Market Regional Image

Key Players and Competitive Insights

The Ticagrelor Market is characterized by a dynamic competitive landscape, driven by the increasing prevalence of cardiovascular diseases and the growing demand for effective antiplatelet therapies. Key players such as AstraZeneca (GB), Bristol-Myers Squibb (US), and Sanofi (FR) are strategically positioned to leverage their extensive research and development capabilities, focusing on innovation and partnerships to enhance their market presence. AstraZeneca (GB) has been particularly proactive in expanding its product portfolio through collaborations, which appears to strengthen its competitive edge in this sector.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Pfizer (US) and Novartis (CH) is significant, as they continue to innovate and adapt to changing market demands, thereby shaping the competitive environment.

In November AstraZeneca (GB) announced a strategic partnership with a leading biotechnology firm to develop a novel formulation of Ticagrelor aimed at improving patient adherence. This collaboration is expected to enhance AstraZeneca's product offerings and potentially capture a larger share of the market by addressing patient needs more effectively. The strategic importance of this move lies in its potential to differentiate AstraZeneca's products in a crowded marketplace.

In October Bristol-Myers Squibb (US) launched a new marketing campaign focused on the benefits of Ticagrelor in combination therapies for patients with complex cardiovascular conditions. This initiative not only aims to boost sales but also reinforces the company's commitment to educating healthcare professionals about the evolving treatment landscape. The campaign's strategic significance is underscored by its potential to enhance brand loyalty and increase market penetration.

In September Sanofi (FR) expanded its distribution network in emerging markets, particularly in Asia and Africa, to increase access to Ticagrelor. This strategic move is likely to enhance Sanofi's market presence in regions with rising cardiovascular disease rates, thereby positioning the company for future growth. The expansion reflects a broader trend of companies seeking to tap into underserved markets, which may yield substantial returns in the long run.

As of December current competitive trends in the Ticagrelor Market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in drug development and marketing strategies. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on innovation, technology, and supply chain reliability, as companies strive to meet the demands of a more discerning healthcare market.

Key Companies in the Ticagrelor Market include

Industry Developments

    • September 02, 2019, the Strs Ohio (the US), a main worldwide institutional financial backer, reported the securing of another stake in Phase Bio Pharmaceuticals Inc. (the US), a clinical-stage biopharmaceutical organization. 
    • haseBio centers around the turn of events and commercialization of novel treatments and medications, for example, an inversion specialist for the antiplatelet drug ticagrelor

Future Outlook

Ticagrelor Market Future Outlook

The Ticagrelor Market is projected to grow at a 6.14% CAGR from 2025 to 2035, driven by increasing cardiovascular disease prevalence and advancements in drug formulations.

New opportunities lie in:

  • Expansion into emerging markets with tailored pricing strategies.
  • Development of combination therapies to enhance efficacy and patient adherence.
  • Investment in digital health platforms for remote patient monitoring and engagement.

By 2035, the Ticagrelor Market is expected to solidify its position as a leading therapeutic option in cardiovascular care.

Market Segmentation

Ticagrelor Market Application Outlook

  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Peripheral Artery Disease
  • Stroke Prevention

Ticagrelor Market Formulation Type Outlook

  • Tablet
  • Injection

Ticagrelor Market Therapeutic Area Outlook

  • Cardiology
  • Neurology
  • Vascular Medicine

Ticagrelor Market Patient Demographics Outlook

  • Geriatric Patients
  • Adult Patients
  • Pediatric Patients

Ticagrelor Market Route of Administration Outlook

  • Oral
  • Intravenous

Report Scope

MARKET SIZE 20242024.94(USD Million)
MARKET SIZE 20252172.45(USD Million)
MARKET SIZE 20353916.71(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)6.14% (2025 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Million
Key Companies ProfiledAstraZeneca (GB), Boehringer Ingelheim (DE), Sanofi (FR), Bristol-Myers Squibb (US), Pfizer (US), Novartis (CH), Mylan (US), Teva Pharmaceutical Industries (IL)
Segments CoveredApplication, Route of Administration, Patient Demographics, Therapeutic Area, Formulation Type
Key Market OpportunitiesEmerging trends in personalized medicine enhance growth potential in the Ticagrelor Market.
Key Market DynamicsRising demand for Ticagrelor driven by increasing cardiovascular disease prevalence and evolving treatment protocols.
Countries CoveredNorth America, Europe, APAC, South America, MEA

Market Highlights

Author
Kinjoll Dey
Research Analyst Level I

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch
Leave a Comment

FAQs

At what CAGR is the ticagrelor market projected to grow in the forecast period (2023-2030)?

Ticagrelor market projected to grow at approximately 6.4% CAGR during the assessment period (2023-2032).

How much is the ticagrelor market worth in the future?

The valuation of the ticagrelor market is estimated to increase to USD 3.32 Billion by the end of 2032.

What are the major tailwinds pushing the growth of the ticagrelor market?

Large patient pool suffering from heart problems and increasing product development, commercialization, and improving funding for R&D by the market players are major tailwinds pushing the growth of the ticagrelor market.

Which region holds the largest share in the ticagrelor market?

North America holds the largest share in the ticagrelor market, followed by Europe and the Asia Pacific, respectively.

Who are the top players in the ticagrelor market?

AstraZeneca, Eli Lilly, Boehringer, Ingelheim, Pfizer, Amgen, Merck, Roche, GSK, Boehringer, Alexion, and Amgen, are some of the top players operating in the global ticagrelor market.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓